Format

Send to

Choose Destination
Chest. 2001 Jul;120(1):258-70.

Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.

Author information

1
GlaxoSmithKline Research and Development, Uxbridge, Middlesex, UK. mj0859@glaxowellcome.co.uk

Abstract

beta(2)-Adrenergic agonists are commonly used as bronchodilators to treat patients with COPD. In addition to prolonged bronchodilation, long-acting beta(2)-agonists (LABAs) exert other effects that may be of clinical relevance. These include inhibition of airway smooth-muscle cell proliferation and inflammatory mediator release, as well as nonsmooth-muscle effects, such as stimulation of mucociliary transport, cytoprotection of the respiratory mucosa, and attenuation of neutrophil recruitment and activation. This review details the possible alternative mechanisms of action of the LABAs, salmeterol and formoterol, in COPD.

PMID:
11451847
DOI:
10.1378/chest.120.1.258
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center